Europe's COVID-19 Procedures ‘Must Not Be Delayed’
Regulatory Network Needs To Work In Harmony
Executive Summary
The coronavirus could have serious adverse effects on regulatory procedures at both European Medicines Agency and EU member state level. A new business continuity plan describes how procedures will be prioritized if problems arise.
You may also be interested in...
EU Allows ‘Freezing’ & ‘Rolling Back’ Of Regulatory Timelines Due To COVID-19
Guidance is now available to help drug companies that use the EU mutual recognition and decentralized procedures to handle regulatory processes during the COVID-19 crisis.
EU Moves To Ease Regulatory Burden On Pharma
Regulatory authorities have adapted the EU medicines framework to help pharmaceutical companies cope with the consequences of the COVID-19 pandemic.
Industry & Regulators To Align Advice on COVID-19 Vaccine Updates
A multi-stakeholder workshop looked at the data needed to support updates to vaccine composition and the time required by manufacturers to update their vaccines, change their manufacturing processes and prepare approval applications.